Nuvalent Inc - Ordinary Shares - Class A Aktie News

CAMBRIDGE, Mass. , Nov. 26, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced underwritten public offering of 4,950,496 shares of Class A common stock at a price to the public of $101.00 per share.

NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass. , Nov. 19, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the U.S. Food and Drug Administration (...

Sold 1,447,267 shares, a net position change of $110.43 million Post-trade stake: 0 shares, $0 value The position was previously 13.8% of the fund's AUM as of the prior quarter, marking a significant portfolio shift

CAMBRIDGE, Mass. , Nov. 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of an underwritten public offering of shares of Class A common stock at a price to the public of $101.00 per share.

CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that it has commenced an underwritten public offering of shares of Class A common stock.

Nuvalent, Inc. ( NUVL ) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer November 17, 2025 8:00 AM EST Company Participants Chelcie Lister James Porter - CEO, President & Director Christopher Turner - Chief Medical Officer Alexandra Balcom - CFO & Treasurer Darlene Noci - Chief Development Officer Conference Call Participants Bradley Ca...

Nuvalent said Monday almost a third of patients with a hard-to-treat form of lung cancer responded to its experimental treatment.